Treatment of Alzheimer's disease. Molecular pathology versus neurotransmitter-based therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 1978786.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cortical inhibitory neurotransmitters, neuropeptides, dopamine and noradrenaline are probably either not selectively or not critically affected in AD. It is, however, likely that a key change is shrinkage or loss of corticocortical pyramidal neurones, which probably use glutamate as their transmitter. This depletion appears to be circumscribed and clinically relevant.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Chromosomes, Human, Pair 21
- Cloning, Molecular
- Glutamates
- Neurotransmitter Agents
- Protease Inhibitors
- Protein Precursors